Glenmark Pharmaceuticals Inc USA (Glenmark), has been granted tentative approval by the United States Food & Drug Administration (FDA) for its lacosamide tablets, 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat tablets, 50 mg, 100 mg, 150 mg and 200 mg of UCB Inc.